(S1 (S (NP (NP (NP (NN Aflibercept)) (PRN (-LRB- -LRB-) (NP (NN AVE0005)) (-RRB- -RRB-))) (: :) (NP (NP (DT an) (JJ alternative) (NN strategy)) (PP (IN for) (S (VP (VBG inhibiting) (NP (NP (NN tumour) (NN angiogenesis)) (PP (IN by) (NP (JJ vascular) (JJ endothelial) (NN growth) (NNS factors)))))))) (. .))))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (JJ Aberrant) (NN angiogenesis)) (VP (VBZ is) (NP (NP (DT a) (JJ landmark) (NN feature)) (PP (IN in) (NP (NN cancer))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (NP (NN proliferation)) (, ,) (NP (NN growth)) (CC and) (NP (NN metastasis)))))) (, ,) (CC and) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (JJ various) (JJ pro-angiogenic) (NNS factors))))))))))) (. .))))
(S1 (S (S (NP (DT The) (NN VEGF) (NN pathway)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (RBS most) (ADJP (ADJP (JJ important)) (CC and) (ADJP (JJ best-studied))) (JJ angiogenic) (NNS pathways)))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (DT this) (NN pathway)))) (VP (MD may) (VP (VB provide) (NP (NP (JJ clinical) (NNS benefits)) (PP (TO to) (NP (NN cancer) (NNS patients))))))) (. .)))
(S1 (S (NP (NP (NNS OBJECTIVES)) (: :) (S (NP (NP (NNS Strategies)) (VP (TO to) (VP (VB inhibit) (NP (DT the) (NN VEGF) (NN pathway)))) (, ,) (PP (VBG including) (NP (NP (NP (NNS antibodies)) (PP (TO to) (NP (NN VEGF)))) (, ,) (NP (NP (NNS antibodies)) (PP (TO to) (NP (NP (DT the) (JJ extracellular) (NN domain)) (PP (IN of) (NP (NP (NN VEGFR-1)) (CC or) (NP (NN VEGFR-2))))))) (, ,) (NP (NP (NN decoy) (NNS receptors)) (PP (IN for) (NP (NN VEGF)))) (CC and) (NP (NP (NN tyrosine) (NN kinase) (NNS inhibitors)) (PP (IN of) (NP (NNS VEGFRs)))))) (, ,)) (VP (VBP are) (VP (VBN summarized)))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (DT This) (NN review)) (VP (VP (VBZ outlines)) (CC and) (VP (VBZ compares) (NP (NP (DT the) (JJ latest) (NN development)) (PP (IN of) (NP (DT these) (NNS strategies)))) (, ,) (PP (IN with) (NP (NP (NN emphasis)) (PP (IN on) (NP (NP (NN aflibercept)) (, ,) (NP (NP (DT a) (JJ novel) (NN decoy) (NN fusion) (NN protein)) (PP (IN of) (NP (NP (NP (NN domain) (CD 2)) (PP (IN of) (NP (NN VEGFR-1)))) (CC and) (NP (NP (NN domain) (CD 3)) (PP (IN of) (NP (NN VEGFR-2)))))) (PP (IN with) (NP (NP (DT the) (NN Fc) (NN fragment)) (PP (IN of) (NP (NN IgG1))))))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN Aflibercept)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (JJ early) (JJ clinical) (NN activity)))))))) (. .))))
(S1 (S (S (NP (JJ Multiple) (NNS studies)) (VP (VBP are) (ADJP (JJ ongoing) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ clinical) (NNS benefits)) (PP (IN of) (NP (NN aflibercept))) (PP (IN in) (NP (NN cancer) (NNS patients)))))))))) (. .)))
